Journal: Journal of Cancer

Article Title: Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067.

doi: 10.7150/jca.35426

Figure Lengend Snippet: Figure 2. CDK9 expression in chordoma cell lines and tissues. (A) CDK9 expression in chordoma cell lines. (B and C) CDK9 expression in chordoma tissues. There are 2 isoforms of the CDK9 protein: the 42 KD CDK9 isoform and the 55 KD isoform. The smaller 42 KD isoform was the first identified isoform. Expression of CDK9 (55KD band) was normalized to α-Tubulin. (D) Cellular localization of CDK9 in UCH2 and CH22 cells was assessed by immunofluorescence with antibodies to CDK9 and actin.

Article Snippet: Monoclonal rabbit anti-CDK9, anti-p-RNAP II Ser-2 (13499S), antiSurvivin (2808S), anti-Bax (5023S), anti-Mcl-1(94296) and monoclonal mouse anti-α-tubulin (3874) antibodies were purchased from Cell Signaling Technology (Danvers, MA).

Techniques: Expressing, Immunofluorescence

Journal: Journal of Cancer

Article Title: Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067.

doi: 10.7150/jca.35426

Figure Lengend Snippet: Figure 3. Effect of CDK9 inhibition by siRNA on chordoma cell lines. (A and B) After transfected with increasing concentrations of CDK9 specific siRNA or nonspecific siRNA for 3 days, cell viability was determined by MTT assay after siRNA transfection in both UCH2 and CH22 cells. *p<0.05. (C and D) The morphology of UCH2 and CH22 cell lines changed after 3 days of siRNA transfection. α-Tubulin was used as a loading control. (E and F) The proteins of CDK9 and downstream proteins p-RNA II ser2 and Mcl-1 in cells were examined by Western blot after 3 days of siRNA transfection.

Article Snippet: Monoclonal rabbit anti-CDK9, anti-p-RNAP II Ser-2 (13499S), antiSurvivin (2808S), anti-Bax (5023S), anti-Mcl-1(94296) and monoclonal mouse anti-α-tubulin (3874) antibodies were purchased from Cell Signaling Technology (Danvers, MA).

Techniques: Inhibition, Transfection, MTT Assay, Control, Western Blot

Journal: Journal of Cancer

Article Title: Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067.

doi: 10.7150/jca.35426

Figure Lengend Snippet: Figure 4. Effect of CDK9 inhibitor treatment on chordoma cell lines. (A and B) After exposure to increasing concentrations of CDK9 inhibitor for 120 h, cell viability was decreased in a dose-dependent manner in both UCH2 and CH22 cells, with the IC50 values for LDC000067 at 3.22 µM and 4.47 µM, respectively. (C) After incubation of UCH2 and CH22 cell lines with 1.25 µM, 2.5µM, 5.0µM, and 10.0 µM LDC000067 for 48 h, they showed a strong decrease of p-RNA II ser2 and Mcl-1 expression with increasing LDC000067 concentration. α-Tubulin was used as a loading control.

Article Snippet: Monoclonal rabbit anti-CDK9, anti-p-RNAP II Ser-2 (13499S), antiSurvivin (2808S), anti-Bax (5023S), anti-Mcl-1(94296) and monoclonal mouse anti-α-tubulin (3874) antibodies were purchased from Cell Signaling Technology (Danvers, MA).

Techniques: Incubation, Expressing, Concentration Assay, Control